Cargando…

Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions

Endometrial cancer is the most common gynecological cancer in the developed world, and it is one of the few cancer types that is becoming more prevalent and leading to more deaths in the USA each year. The majority of endometrial tumors are considered to be hormonally driven, where estrogen signalin...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez, Adriana C., Blanchard, Zannel, Maurer, Kathryn A., Gertz, Jason
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542701/
https://www.ncbi.nlm.nih.gov/pubmed/30712080
http://dx.doi.org/10.1007/s12672-019-0358-9
_version_ 1783422965738635264
author Rodriguez, Adriana C.
Blanchard, Zannel
Maurer, Kathryn A.
Gertz, Jason
author_facet Rodriguez, Adriana C.
Blanchard, Zannel
Maurer, Kathryn A.
Gertz, Jason
author_sort Rodriguez, Adriana C.
collection PubMed
description Endometrial cancer is the most common gynecological cancer in the developed world, and it is one of the few cancer types that is becoming more prevalent and leading to more deaths in the USA each year. The majority of endometrial tumors are considered to be hormonally driven, where estrogen signaling through estrogen receptor α (ER) acts as an oncogenic signal. The major risk factors and some treatment options for endometrial cancer patients emphasize a key role for estrogen signaling in the disease. Despite the strong connections between estrogen signaling and endometrial cancer, important molecular aspects of ER function remain poorly understood; however, progress is being made in our understanding of estrogen signaling in endometrial cancer. Here, we discuss the evidence for the importance of estrogen signaling in endometrial cancer, details of the endometrial cancer-specific actions of ER, and open questions surrounding estrogen signaling in endometrial cancer.
format Online
Article
Text
id pubmed-6542701
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-65427012019-06-01 Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions Rodriguez, Adriana C. Blanchard, Zannel Maurer, Kathryn A. Gertz, Jason Horm Cancer Review Endometrial cancer is the most common gynecological cancer in the developed world, and it is one of the few cancer types that is becoming more prevalent and leading to more deaths in the USA each year. The majority of endometrial tumors are considered to be hormonally driven, where estrogen signaling through estrogen receptor α (ER) acts as an oncogenic signal. The major risk factors and some treatment options for endometrial cancer patients emphasize a key role for estrogen signaling in the disease. Despite the strong connections between estrogen signaling and endometrial cancer, important molecular aspects of ER function remain poorly understood; however, progress is being made in our understanding of estrogen signaling in endometrial cancer. Here, we discuss the evidence for the importance of estrogen signaling in endometrial cancer, details of the endometrial cancer-specific actions of ER, and open questions surrounding estrogen signaling in endometrial cancer. Springer US 2019-02-02 /pmc/articles/PMC6542701/ /pubmed/30712080 http://dx.doi.org/10.1007/s12672-019-0358-9 Text en © The Author(s) 2019 https://creativecommons.org/licenses/by/4.0/Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Rodriguez, Adriana C.
Blanchard, Zannel
Maurer, Kathryn A.
Gertz, Jason
Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions
title Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions
title_full Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions
title_fullStr Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions
title_full_unstemmed Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions
title_short Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions
title_sort estrogen signaling in endometrial cancer: a key oncogenic pathway with several open questions
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542701/
https://www.ncbi.nlm.nih.gov/pubmed/30712080
http://dx.doi.org/10.1007/s12672-019-0358-9
work_keys_str_mv AT rodriguezadrianac estrogensignalinginendometrialcancerakeyoncogenicpathwaywithseveralopenquestions
AT blanchardzannel estrogensignalinginendometrialcancerakeyoncogenicpathwaywithseveralopenquestions
AT maurerkathryna estrogensignalinginendometrialcancerakeyoncogenicpathwaywithseveralopenquestions
AT gertzjason estrogensignalinginendometrialcancerakeyoncogenicpathwaywithseveralopenquestions